FDMT — 4D Molecular Therapeutics, Inc. stock price, charts and financials

QT694D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
15.22
+0.54+3.68%
OverviewShort InterestFilings
FDMTQT694D Molecular Therapeutics, Inc.·NASDAQ
15.22+3.68%
Analyst
Up 3.7% — Cantor Fitzgerald upgraded to Overweight, price target $20.
High confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-2.48Insider Own35.91%Shs Outstand52.28MPerf Week15.57%
Market Cap795.64MForward P/E-EPS next Y-4.09Insider Trans-1.93%Shs Float39.01MPerf Month-9.19%
Enterprise Value468.64MPEG-EPS next Q-1.04Inst Own-Short Float30.94%Perf Quarter57.56%
Income-140.00MP/S9.36EPS this Y-66.77%Inst Trans-Short Ratio12.62Perf Half Y69.49%
Sales85.00MP/B1.95EPS next Y1.11%ROA-36.37%Short Interest12.07MPerf YTD102.93%
Book/sh7.80P/C2.20EPS next 5Y-ROE-41.33%52W High16.93 -10.10%Perf Year128.53%
Cash/sh6.91P/FCF-EPS past 3/5Y-ROIC-43.77%52W Low6.47 135.24%Perf 3Y-4.04%
Dividend Est.-EV/EBITDA-Sales past 3/5Y204.86% 43.44%Gross Margin42.00%Volatility5.83% 6.15%Perf 5Y-54.70%
Dividend TTM-EV/Sales5.51EPS Y/Y TTM11.74%Oper. Margin-214.24%ATR (14)0.94Perf 10Y-
Dividend Ex-Date-Quick Ratio8.03Sales Y/Y TTM-Profit Margin-194.74%RSI (14)61.01Recom2.29
Dividend Gr. 3/5Y-Current Ratio8.03EPS Q/Q-6.12%SMA204.36%Beta2.70Target Price26.00
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA5019.50%Rel Volume1.87Prev Close14.68
Employees196LT Debt/Eq0.03EarningsNov 10SMA20048.47%Avg Volume953.34KPrice15.22
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.-2.29% 4.45%Net Debt/EBITDA0.17Volume1,786,425Change3.68%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-14-26UpgradeCantor FitzgeraldNeutral → Overweight$20
Aug-13-26ReiteratedGoldman SachsBuy$33 → $32
May-08-26ReiteratedGoldman SachsBuy$38 → $33
Nov-11-25ReiteratedBarclaysOverweight$45 → $33
Oct-31-25ReiteratedLeerink PartnersOutperform$17
Oct-21-25ReiteratedRBC CapitalOutperform$40 → $26
Sep-23-24DowngradeCantor FitzgeraldOverweight → Neutral
Sep-19-24ReiteratedBMO CapitalOutperform$40
Sep-19-24ReiteratedLoop Capital Markets$39
Apr-15-24ReiteratedBarclays$45
Latest News· Times ET
Sep-17-26
Sep-17-2606:48AM
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcriptseekingalpha.com
Sep-14-26
Sep-14-2606:01PM
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
04:31AM
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For MondayBenzinga
Sep-11-26
Sep-11-2612:05PM
4DMT Announces New Employment Inducement Grantsglobenewswire.com
Aug-25-26
Aug-25-2604:00AM
4DMT to Participate in Upcoming Investor Conferencesglobenewswire.com
Aug-24-26
Aug-24-2611:55PM
4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DEdefenseworld.net
Aug-23-26
Aug-23-2611:54PM
Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMTdefenseworld.net
Aug-17-26
Aug-17-2611:45PM
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?defenseworld.net
07:51PM
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s WhyYahoo
Aug-14-26
Aug-14-2612:05PM
4DMT Announces New Employment Inducement Grantsglobenewswire.com
Aug-13-26
Aug-13-2603:06PM
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimateszacks.com
12:05PM
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestonesglobenewswire.com
Jul-31-26
Jul-31-2607:52AM
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37Benzinga
Jul-29-26
Jul-29-2611:22AM
10 Stock Picks to Celebrate 45 Years of Schaeffer'sschaeffersresearch.com
Jul-20-26
Jul-20-2610:16AM
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion OpportunitySeekingAlpha
Company

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue85021——————
Cost of Goods Sold Incl. D&A814197——————
Gross Profit78-141-76——————
Selling, General and Administrative Excl. Other494736——————
Research and Development19614197——————
Other Operating Expense-8-141-97——————
Operating Income-160-188-113——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)192712——————
Net Income Before Taxes-140-161-101——————
Income Taxes
000——————
Consolidated Net Income-140-161-101——————
Net Income From Continuing Operations-140-161-101——————
Net Income-140-161-101——————
EPS (Recurring)-2.42-2.98-2.58——————
EPS (Basic, Before Extraordinaries)-2.42-2.98-2.58——————
EPS (Diluted)-2.42-2.98-2.58——————
EBITDA-132-154-97——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio5.12—37.63——————
Gross Margin91.76—-361.90——————
Operating Margin-188.24—-538.10——————
Net Margin-164.71—-480.95——————
Shares Outstanding585439——————
Market Capitalization435301790——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$18.65$14.56$10.46$6.37$2.27● Close Price0.00M0.38M0.76M1.15M1.53MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kirn DavidSee RemarksSep 14 '26Sale13.9058,333811,004767,486Sep 16
Bizily ScottChief Legal OfficerSep 01 '26Sale14.005848,1768,617Sep 03
Bizily ScottChief Legal OfficerSep 01 '26Option Exercise6.495843,7909,201Sep 03
Kirn DavidSee RemarksAug 19 '26Option Exercise4.1450,000207,000894,895Aug 21
Kirn DavidSee RemarksAug 19 '26Sale15.7569,0761,088,273825,819Aug 21
Bizily ScottChief Legal OfficerAug 17 '26Option Exercise4.141,6356,76910,252Aug 17
Bizily ScottChief Legal OfficerAug 17 '26Sale12.201,63519,9478,617Aug 17
Bizily ScottChief Legal OfficerAug 13 '26Option Exercise4.141,6356,76961,336Aug 17
Bizily ScottChief Legal OfficerAug 13 '26Sale12.001,63519,6208,617Aug 17
Kirn DavidSee RemarksAug 04 '26Sale10.2326,842274,596844,895Aug 05
Kirn DavidSee RemarksAug 03 '26Sale10.0512,415124,722871,737Aug 04
Kirn DavidSee RemarksJul 10 '26Sale12.0315,725189,233884,152Jul 14
Kirn DavidSee RemarksJul 09 '26Sale12.8742,608548,177899,877Jul 14
Bizily ScottChief Legal OfficerJun 30 '26Option Exercise6.206,56640,70015,183Jul 02
Bizily ScottChief Legal OfficerJun 30 '26Sale14.006,56691,9248,617Jul 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.